-
07:13:27 PM

EIGR Stock News

03/16/23 4:28 PM
Nasdaq : EIGR
earnings
Eiger BioPharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today reported financial results for fourth quarter and full year 2022 and provided a business update. "In December, we announced that both our lonafarnib-based...
RHEA-AI
positive
02/08/23 5:00 PM
Nasdaq : EIGR
clinical trialcovid-19
New England Journal of Medicine Publishes Positive Phase 3 TOGETHER Results with Peginterferon Lambda in COVID-19
Eiger BioPharmaceuticals Inc., a commercial-stage biopharmaceutical company focused on the development of innovative therapies for hepatitis delta virus and other serious diseases, today announced the publication of data from the investigator-sponsored Phase 3 TOGETHER study in patients with COVID-19 in the New England Journal of Medicine. The...
RHEA-AI
neutral
12/08/22 8:00 AM
Nasdaq : EIGR
clinical trial
Eiger Announces Both Lonafarnib-based Treatments in Pivotal Phase 3 D-LIVR Trial in Hepatitis Delta Virus (HDV) Achieved Statistical Significance Against Placebo in Composite Primary Endpoint
- Lonafarnib/ritonavir response rate of 10.1% (p=0.0044) - Lonafarnib/ritonavir in combination with peginterferon alfa response rate of 19.2% (p<0.0001) - Peginterferon alfa comparator arm, included for contribution of effect, response rate of 9.6% - Key secondary endpoint of proportion of patients
RHEA-AI
neutral